GlassScriptPhysician profile
Charles A Ozborn
NPI 1053373662
$500.64
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $106 · 2021: $142 · 2022: $97.66.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $240.09 | 2019-2022 | |
| Amgen INC. | $73.71 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $43.44 | 2020-2021 | |
| Abbvie INC. | $35.02 | 2022 | |
| Amarin Pharma, INC. | $29.97 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.42 | 2021 | |
| Indivior INC. | $17.45 | 2019 | |
| Avanir Pharmaceuticals, INC. | $15.47 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.91 | 2021 | |
| Novartis Pharmaceuticals Corporation | $11.16 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Ozborn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.